Why the study?
Does hydroxyethyl starch (HES Pz) infusion reduce myocardial reperfusion injury in a canine open-chest model of ischemia-reperfusion?
Does hydroxyethyl starch (HES Pz) infusion reduce myocardial reperfusion injury in a canine open-chest model of ischemia-reperfusion?
In a canine model of ischemia-reperfusion, hydroxyethyl starch (HES Pz) infusion significantly reduced infarct size and myocardial edema compared to Ringer's lactate or albumin.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in canine ischemia-reperfusion; leaves open translation to human reperfusion injury.
We assessed the value of a fraction of hydroxyethyl starch (HES Pz) in reducing the myocardial reperfusion injury in a canine open-chest model in which 1 hour of left anterior descending coronary artery occlusion was followed by 24 hours of reperfusion. Three treatment infusions (5% of blood volume) were compared: Ringer's lactate, serum albumin, and HES Pz (70% of the macromolecules between 100,000 and 1,000,000 d). When compared with Ringer's lactate and albumin, HES Pz significantly reduced the ratio of 24-hour infarct size to pretreatment area at risk (3% vs 19% and 16%, respectively) and myocardial water content (0.5% vs 3% and 1%). Potassium content differences between injured and normal myocardium were significantly less in the infarct regions of animals receiving HES Pz. In the canine model, HES Pz reduced 1-hour myocardial ischemia reperfusion injury significantly.
No takes yet. Share an insight, caveat, or question.
Bashir Zikria (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: